Nebivolol and valsartan as a fixed-dose combination for the treatment of hypertension

摘要

Introduction: The fixed-dose combination of nebivolol and valsartan drug has been clinically evaluated and demonstrated to represent a unique combination of nebivolol, a selective beta(1)-adrenoceptor antagonist and a beta(3)-adrenoceptor agonist; beta(3) receptor activation increases endothelial nitric oxide and produces vasodilation. Valsartan is highly selective angiotensin AT(1) receptor blocker and exerts its major pharmacological effect by decreasing angiotensin II-induced vasoconstriction and production of aldosterone. The addition of nebivolol counteracts the effects of increased angiotensin II concentrations resulting from potent AT(1) blockade. This review describes a recently completed trial establishing the efficacy of the nebivolol/valsartan combination.